Innovent Biologi Stock Price, News & Analysis

Innovent Biologics presented clinical data for IBI188, an anti-CD47 monoclonal antibody, at the 2022 ASH Annual Meeting. This Phase Ib study assessed IBI188 coupled with Azacitidine in newly diagnosed higher risk myelodysplastic syndrome (MDS). The results showed a 100% objective response rate (ORR) after 6 cycles and a 63.3% complete response rate (CRR) in 30 patients. 94.6% of participants experienced treatment-related adverse events, yet the therapy demonstrated promising anti-tumor activity. Further updates on clinical findings are expected as the study progresses.

Innovent Biologics has presented updated Phase Ib clinical data for IBI110, an anti-LAG-3 monoclonal antibody, at the 2022 ESMO-IO Congress. In a study of 20 treatment-naïve patients with advanced squamous non-small cell lung cancer (sqNSCLC), IBI110 combined with sintilimab and chemotherapy achieved an objective response rate (ORR) of 80% and a 12-month progression-free survival (PFS) rate of 60%. Safety results indicated manageable adverse events, with no treatment-related deaths reported. The study is ongoing, with further data expected at future academic conferences.

Innovent Biologics has presented promising Phase Ib clinical data for IBI939, an anti-TIGIT monoclonal antibody, at the 2022 European Society for Medical Oncology Immuno-Oncology Congress. The study evaluated the combination of IBI939 and sintilimab in treating PD-L1-selected non-small cell lung cancer (NSCLC). Among 40 evaluable patients, the objective response rate was 64.3% for the experimental group compared to 57.2% for the control. The median progression-free survival was significantly better at 11.2 months versus 6.4 months. Safety profiles showed a higher incidence of treatment-related adverse events in the experimental group.

Innovent Biologics announced the successful dosing of the first Chinese healthy volunteer in a Phase I study for orismilast (IBI353), a potential best-in-class PDE4 inhibitor. This study focuses on evaluating the drug's pharmacokinetics, safety, and tolerability in healthy subjects to support its development for psoriasis and atopic dermatitis. Innovent aims to accelerate orismilast's development in China, addressing a significant unmet need for effective oral treatments in dermatological diseases.

On November 27, 2022, Innovent Biologics announced it will present clinical data for multiple trials at upcoming international medical conferences, including the ESMO Immuno-Oncology Congress and the ASH Annual Meeting. Key topics include the efficacy of IBI110 in advanced lung cancer and the safety of IBI188 in myelodysplastic syndrome. Innovent, committed to high-quality biopharmaceuticals, has developed a robust pipeline with 35 assets, including 8 approved products. The company's strategic collaborations aim to enhance drug availability in China.

Innovent Biologics announced that the first participant has been dosed in the phase 3 clinical trial (GLORY-1) for mazdutide (IBI362), a dual agonist targeting GLP-1 and glucagon receptors, aimed at treating obesity in Chinese adults. The trial will enroll 600 subjects, assessing weight loss efficacy over 48 weeks. Previous phase 2 results showed a mean weight loss of 11.57%. Given China's rising obesity rates, mazdutide's potential for significant health improvements is crucial. Successful outcomes may lead to a new treatment option for obesity, promising better metabolic health for patients.

Innovent Biologics presented updated results from the Phase Ia trial of IBI351 (GFH925), a KRAS^G12C inhibitor, at the 2022 CSCO Annual Meeting. The trial included 67 patients with advanced solid tumors, predominantly non-small cell lung cancer (NSCLC). Key findings showed a 50.9% overall response rate (ORR) and 92.7% disease control rate (DCR) for evaluable NSCLC patients. No dose-limiting toxicities (DLTs) were reported, and treatment was well tolerated. A registrational trial is ongoing, aiming to further investigate IBI351's potential.

Innovent Biologics announced the results of a phase 3 clinical study (CREDIT-1) for tafolecimab (IBI306), a PCSK9 monoclonal antibody, in Chinese patients with non-familial hypercholesterolemia. The study enrolled 618 subjects and demonstrated significant reductions in LDL-C levels: -65.0% for 450 mg Q4W and -57.3% for 600 mg Q6W compared to placebo (both P < 0.0001). Tafolecimab had a favorable safety profile similar to other PCSK9 inhibitors. The drug's New Drug Application is under review in China, potentially leading to it being the first approved locally-developed PCSK9 inhibitor in the country.

Innovent Biologics has initiated a Phase I clinical trial for its anti-Claudin18.2 monoclonal antibody-drug conjugate, IBI343, marking a significant milestone as the first ADC candidate from Innovent's pipeline to enter clinical evaluation. The trial, taking place in Australia, aims to assess the safety and preliminary efficacy of IBI343 in patients with advanced solid tumors. Claudin 18.2 represents a promising target for treating gastric and pancreatic cancers, addressing a substantial unmet medical need given the limitations of current therapies.